KALA BIO, Inc. KALA
Set alert
At close
Pre-market · Nov 2, 4:51 AM ET
- YTD
- -99.40%
- 1 year
- -99.58%
- Open
- 0.175
- Prev close
- 0.1751
- Mkt cap
- 3.20M
- Vol
- 246.11K
- Avg vol
- 1.51M
- EPS
- -10.71
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.163
- High
- 0.1832
- Forward P/E
- -0.90
- Beta
- -2.14
- Short ratio
- 1.91
- Inst. own
- 48.13%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.42
- 200-d avg
- 6.50
- 1y target
- 15.00
Key statistics
- Market cap
- 27.66M
- Enterprise value
- 15.27M
- Trailing P/E
- 0.00
- Forward P/E
- -0.90
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.21
- EPS (TTM)
- -11.67
- Beta
- -2.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -20.51M
- Total cash
- 54.20M
- Total debt
- 36.80M
- Return on equity
- -248.11%
- Shares outstanding
- 4.61M
- Short % of float
- 0.85%
- 50-day average
- 6.42
- 200-day average
- 6.50
Analyst view
Consensus: none
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -2.47.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -2.43 | -1.93 | +0.50 | +20.58% |
| Aug 6, 2024 | Jun 1, 2024 | -4.41 | -3.16 | +1.25 | +28.34% |
| May 14, 2024 | Mar 1, 2024 | -2.89 | -4.20 | -1.31 | -45.33% |
| Mar 29, 2024 | Dec 1, 2023 | -3.62 | -3.18 | +0.44 | +12.15% |
| Nov 13, 2023 | Sep 1, 2023 | -2.15 | -3.41 | -1.26 | -58.60% |
| Aug 4, 2023 | Jun 1, 2023 | -3.19 | -4.36 | -1.17 | -36.68% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 19, 2024 | Oppenheimer | reit | Outperform | Outperform |
| May 17, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 2, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 1, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Nov 17, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About KALA BIO, Inc.
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kalarx.com
News
Your note
Sign in to keep a note on KALA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAZEMORE TODD M | President | Sale | Jun 25, 2024 | 22,385 |
| BLUMENKRANZ MARK S | Director | Stock Award(Grant) | Jun 10, 2024 | 182,821 |
| BRAZZELL ROMULUS KIM | Officer | Sale | Jun 25, 2024 | 83,982 |
| IWICKI MARK T. | Chief Executive Officer | Sale | Jun 25, 2024 | 263,755 |
| KHARABI DARIUS | Officer | Sale | Jun 25, 2024 | 59,728 |
| KOVEN ANDREW IAN | Director | Stock Award(Grant) | Jun 10, 2024 | 13,922 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 19.33% | 891,335 | 5.35M | Sep 29, 2024 |
| SR One Capital Management, LP | 9.62% | 443,661 | 2.66M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 6.64% | 306,067 | 1.84M | Sep 29, 2024 |
| O'Connor, A Distinct Business Unit of UBS Asset Mgmt Americas (LLC) | 3.53% | 162,663 | 975.98K | Sep 29, 2024 |
| Millennium Management Llc | 3.05% | 140,731 | 844.39K | Sep 29, 2024 |
| Vanguard Group Inc | 1.16% | 53,570 | 321.42K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.57% | 26,442 | 158.65K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.57% | 26,296 | 157.78K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 20,825 | 124.95K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 8,351 | 50.11K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 4,997 | 29.98K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 1,482 | 8.89K | Oct 30, 2024 |